ICU Medical, Inc. (ICUI)
ICUI Stock Price Chart
Explore ICU Medical, Inc. interactive price chart. Choose custom timeframes to analyze ICUI price movements and trends.
ICUI Company Profile
Discover essential business fundamentals and corporate details for ICU Medical, Inc. (ICUI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Instruments & Supplies
IPO Date
31 Mar 1992
Employees
15.00k
Website
https://www.icumed.comCEO
Vivek Jain
Description
ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.
ICUI Financial Timeline
Browse a chronological timeline of ICU Medical, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is $1.91, while revenue estimate is $533.39m.
Earnings released on 7 May 2026
EPS came in at $1.97 surpassing the estimated $1.78 by +10.67%, while revenue for the quarter reached $525.77m , beating expectations by +0.98%.
Earnings released on 19 Feb 2026
EPS came in at $1.91 surpassing the estimated $1.68 by +13.69%, while revenue for the quarter reached $535.94m , beating expectations by +1.01%.
Earnings released on 6 Nov 2025
EPS came in at $2.03 surpassing the estimated $1.43 by +41.96%, while revenue for the quarter reached $536.99m , beating expectations by +4.99%.
Earnings released on 7 Aug 2025
EPS came in at $2.10 surpassing the estimated $1.44 by +45.83%, while revenue for the quarter reached $548.87m , beating expectations by +7.31%.
Earnings released on 8 May 2025
EPS came in at $1.72 surpassing the estimated $1.23 by +39.84%, while revenue for the quarter reached $604.70m , beating expectations by +0.17%.
Earnings released on 27 Feb 2025
EPS came in at $2.11 surpassing the estimated $1.48 by +42.57%, while revenue for the quarter reached $629.81m , beating expectations by +5.13%.
Earnings released on 12 Nov 2024
EPS came in at $1.59 surpassing the estimated $1.25 by +27.20%, while revenue for the quarter reached $589.13m , beating expectations by +2.53%.
Earnings released on 7 Aug 2024
EPS came in at $1.56 surpassing the estimated $0.98 by +59.18%, while revenue for the quarter reached $596.46m , beating expectations by +7.72%.
Earnings released on 7 May 2024
EPS came in at $0.96 surpassing the estimated $0.84 by +14.29%, while revenue for the quarter reached $565.96m , beating expectations by +2.48%.
Earnings released on 27 Feb 2024
EPS came in at $1.57 surpassing the estimated $1.18 by +33.05%, while revenue for the quarter reached $587.99m , beating expectations by +4.43%.
Earnings released on 6 Nov 2023
EPS came in at $1.57 surpassing the estimated $1.29 by +21.71%, while revenue for the quarter reached $553.31m , missing expectations by -1.69%.
Earnings released on 7 Aug 2023
EPS came in at $1.88 surpassing the estimated $1.55 by +21.29%, while revenue for the quarter reached $549.31m , missing expectations by -3.38%.
Earnings released on 8 May 2023
EPS came in at $1.74 surpassing the estimated $1.38 by +26.09%, while revenue for the quarter reached $568.65m , beating expectations by +0.59%.
Earnings released on 27 Feb 2023
EPS came in at $1.60 surpassing the estimated $1.50 by +6.67%, while revenue for the quarter reached $578.01m , missing expectations by -0.13%.
Earnings released on 7 Nov 2022
EPS came in at $1.75 surpassing the estimated $1.41 by +24.11%, while revenue for the quarter reached $597.86m , beating expectations by +5.82%.
Earnings released on 8 Aug 2022
EPS came in at $1.37 falling short of the estimated $1.69 by -18.93%, while revenue for the quarter reached $561.00m , beating expectations by +0.19%.
Earnings released on 9 May 2022
EPS came in at $1.82 surpassing the estimated $1.79 by +1.68%, while revenue for the quarter reached $543.12m , missing expectations by -1.82%.
Earnings released on 24 Feb 2022
EPS came in at $1.82 surpassing the estimated $1.63 by +11.66%, while revenue for the quarter reached $340.53m , beating expectations by +6.45%.
Earnings released on 3 Nov 2021
EPS came in at $2.07 surpassing the estimated $1.79 by +15.64%, while revenue for the quarter reached $336.06m , beating expectations by +6.92%.
Earnings released on 4 Aug 2021
EPS came in at $1.88 surpassing the estimated $1.64 by +14.63%, while revenue for the quarter reached $321.68m , beating expectations by +3.33%.
ICUI Stock Performance
Access detailed ICUI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
